TGN-S15
HPV-induced cancers (e.g., Oropharyngeal Squamous Cell Carcinoma)
PreclinicalActive
Key Facts
Indication
HPV-induced cancers (e.g., Oropharyngeal Squamous Cell Carcinoma)
Phase
Preclinical
Status
Active
Company
About Toragen
Toragen is a private, clinical-stage oncology company pioneering a novel approach to treating HPV-induced cancers by targeting the viral E5 oncoprotein. The company has completed a Phase I trial for its first-generation compound and is now advancing a second-generation candidate, TGN-S15, which has shown improved preclinical efficacy and safety. Operating in a large and growing market with limited effective therapies, Toragen aims to develop a targeted treatment that could be used alone or in combination with existing immunotherapies to improve patient outcomes.
View full company profile